56 Biosimilars In Late-Stage Development Line Up To Challenge Top Biologic Drugs
Executive Summary
Many key biologic drugs, including adalimumab, bevacizumab, rituximab and trastuzumab, are facing biosimilar competition from products that have been either filed or recently approved in Europe, and 56 biosimilars are now at a late stage of clinical development, according to Per Troein of QuintilesIMS.
You may also be interested in...
2017 – Scrip Readers’ Pharma Year In Review
As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.
2017 – Scrip Readers’ Pharma Year In Review
As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.
Firms Advised To Prepare Now For New EU Patent System
After many delays and disagreements, Europe’s Unified Patent Court is expected to open its doors in the first quarter of 2023, offering a more cost-effective option for patent protection and dispute settlement in the EU. The new system includes the possibility of taking out a “unitary patent” offering EU protection in practically all the EU member states. A guide to the key points of the new system is shown below.